These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31871299)

  • 21. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers for glioma immunotherapy: the next generation.
    Sims JS; Ung TH; Neira JA; Canoll P; Bruce JN
    J Neurooncol; 2015 Jul; 123(3):359-72. PubMed ID: 25724916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology.
    Park K
    Yonsei Med J; 2017 Jan; 58(1):1-8. PubMed ID: 27873489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Pursuit of Therapeutic Biomarkers with High-Throughput Cancer Cell Drug Screens.
    Williams SP; McDermott U
    Cell Chem Biol; 2017 Sep; 24(9):1066-1074. PubMed ID: 28736238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
    Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
    Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors.
    Yin A; Moes DJAR; van Hasselt JGC; Swen JJ; Guchelaar HJ
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):720-737. PubMed ID: 31250989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular targets in cancer therapy.
    Kummar S; Doroshow JH
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):267-9. PubMed ID: 23477512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 31. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
    Sardu ML; Poggesi I; De Nicolao G
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
    Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
    Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathology in therapeutics: where are we now, and where are we going?
    Harrison DJ; Faratian D
    Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug Discovery and Development of Innovative Therapeutics--IBC's 13th Annual World Congress. Approaches to cancer therapy.
    Napper A
    IDrugs; 2008 Oct; 11(10):705-9. PubMed ID: 18828066
    [No Abstract]   [Full Text] [Related]  

  • 35. Harnessing the predictive power of preclinical models for oncology drug development.
    Honkala A; Malhotra SV; Kummar S; Junttila MR
    Nat Rev Drug Discov; 2022 Feb; 21(2):99-114. PubMed ID: 34702990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
    Smoragiewicz M; Adjei AA; Calvo E; Tabernero J; Marabelle A; Massard C; Tang J; de Vries EGE; Douillard JY; Seymour L;
    Clin Cancer Res; 2020 Jun; 26(11):2461-2465. PubMed ID: 32086344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
    Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N
    Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.
    Nawaz M; Fatima F; Nazarenko I; Ekström K; Murtaza I; Anees M; Sultan A; Neder L; Camussi G; Valadi H; Squire JA; Kislinger T
    Expert Rev Proteomics; 2016; 13(4):395-409. PubMed ID: 26973172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.